Global Transdermal Scopolamine Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
- Published Date: 2021-04-23
- Report ID: 106431
- Pages: 104
-
Format:
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Transdermal Scopolamine market in this environment.
In terms of revenue, this research report indicated that the global Transdermal Scopolamine market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Transdermal Scopolamine industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Baxter International Inc. aims at producing XX K Units Transdermal Scopolamine in 2020, with XX % production to take place in global market, GlaxoSmithKline plc accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Transdermal Scopolamine Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Transdermal Scopolamine Market
Baxter International Inc.
GlaxoSmithKline plc
Novartis AG
Perrigo Company plc.
Caleb Pharmaceuticals, Inc.
Myungmoon Pharma Co. LTD.
...
...
Major Type of Transdermal Scopolamine Covered in Prudent Markets report:
Tablet Type
Syrups Type
Injections Type
Patch Type
Gel Type
Application Segments Covered in Prudent Markets Market
Hospital
Clinic
Ambulance Center
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Transdermal Scopolamine Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Tablet Type -Product Introduction and Major Manufacturers
1.1.2 Syrups Type -Product Introduction and Major Manufacturers
1.1.3 Injections Type -Product Introduction and Major Manufacturers
1.1.4 Patch Type -Product Introduction and Major Manufacturers
1.1.5 Gel Type -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Transdermal Scopolamine Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis
3.1 China Transdermal Scopolamine Market
3.1.1 Top Companies leading Transdermal Scopolamine Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Transdermal Scopolamine Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)
3.2 EU Transdermal Scopolamine Market
3.2.1 Top Companies leading Transdermal Scopolamine Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Transdermal Scopolamine Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)
3.3 USA Transdermal Scopolamine Market
3.3.1 Top Companies leading Transdermal Scopolamine Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Transdermal Scopolamine Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)
3.4 Japan Transdermal Scopolamine Market
3.4.1 Top Companies leading Transdermal Scopolamine Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Transdermal Scopolamine Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)
3.5 India Transdermal Scopolamine Market
3.5.1 Top Companies leading Transdermal Scopolamine Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Transdermal Scopolamine Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)
3.6 Southeast Asia Transdermal Scopolamine Market
3.6.1 Top Companies leading Transdermal Scopolamine Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Transdermal Scopolamine Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Transdermal Scopolamine Market
3.7.1 Top Companies leading Transdermal Scopolamine Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Transdermal Scopolamine Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)
4.1 Transdermal Scopolamine Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Transdermal Scopolamine Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)
5.1 Global Transdermal Scopolamine Sales and Growth Rate (2021-2027)
5.2 Global Transdermal Scopolamine Sales Value and Growth Rate (2021-2027)
6 Transdermal Scopolamine Competitive Analysis
6.1 Baxter International Inc.
6.1.1 Baxter International Inc. Company Profiles
6.1.2 Baxter International Inc. Product Introduction
6.1.3 Baxter International Inc. Transdermal Scopolamine Production, Revenue (2016-2021)
6.1.4 SWOT Analysis
6.2 GlaxoSmithKline plc
6.2.1 GlaxoSmithKline plc Company Profiles
6.2.2 GlaxoSmithKline plc Product Introduction
6.2.3 GlaxoSmithKline plc Transdermal Scopolamine Production, Revenue (2016-2021)
6.2.4 SWOT Analysis
6.3 Novartis AG
6.3.1 Novartis AG Company Profiles
6.3.2 Novartis AG Product Introduction
6.3.3 Novartis AG Transdermal Scopolamine Production, Revenue (2016-2021)
6.3.4 SWOT Analysis
6.4 Perrigo Company plc.
6.4.1 Perrigo Company plc. Company Profiles
6.4.2 Perrigo Company plc. Product Introduction
6.4.3 Perrigo Company plc. Transdermal Scopolamine Production, Revenue (2016-2021)
6.4.4 SWOT Analysis
6.5 Caleb Pharmaceuticals, Inc.
6.5.1 Caleb Pharmaceuticals, Inc. Company Profiles
6.5.2 Caleb Pharmaceuticals, Inc. Product Introduction
6.5.3 Caleb Pharmaceuticals, Inc. Transdermal Scopolamine Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6 Myungmoon Pharma Co. LTD.
6.6.1 Myungmoon Pharma Co. LTD. Company Profiles
6.6.2 Myungmoon Pharma Co. LTD. Product Introduction
6.6.3 Myungmoon Pharma Co. LTD. Transdermal Scopolamine Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 ...
6.7.1 ... Company Profiles
6.7.2 ... Product Introduction
6.7.3 ... Transdermal Scopolamine Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
7 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
